Phenotyping platform of JMC
Phenotyping platform
In Japan Mouse Clinic, we have developed the two pipelines which are constructed with comprehensive test items.
Pipeline 1
Comprehensive test items examining metabolic, blood/hematic, osseous /skeletal, cancer, cardiovascular, sensory, skin/fur, and neural / behavioral characteristics, construct pipeline 1. Early primary "Fundamental screen" and late secondary "In depth screen" are systematically performed
| Fundamental screen | No. of test |
Screens | Methods | Age(weeks) | ||||||||||||||||||||
| 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | |||||
| P1-01 | Behavior | Open-field test | ||||||||||||||||||||||
| P1-02 | Morphology/ Behavioral/ Sensory |
Modified-SHIRPA |
||||||||||||||||||||||
| P1-03 | Hematology/ Clinical Chemistry |
Hematological test | ||||||||||||||||||||||
| P1-04 | Urinalysis | |||||||||||||||||||||||
| P1-05 | Clinical biochemical test | |||||||||||||||||||||||
| P1-06 | Pathology | Autopsy, Histology | ||||||||||||||||||||||
| In depth screen | P1-07 | Sensory | ABR (Auditory brainstem response) | |||||||||||||||||||||
| P1-08 | Metabolism | IPGTT (Intra-peritoneal glucose tolerance test) | ||||||||||||||||||||||
| P1-09 | Adipocytokine and clinical biochemical test (glucose and adipose related) | |||||||||||||||||||||||
| P1-10 | Sensory | Funduscopy | ||||||||||||||||||||||
| P1-11 | ERG (Electroretinography) | |||||||||||||||||||||||
| P1-12 | Cardiovascular | Blood pressure | ||||||||||||||||||||||
| P1-13 | Metabolism | Body fat percentage and Bone Mineral Density (DEXA) | ||||||||||||||||||||||
| P1-14 | Cardiovascular | ECG (Electrocardiography) | ||||||||||||||||||||||
Pipeline 2
Result of mouse behavior examination comes under the considerable influence of its own prior experiences. And the multilateral approaches are necessary for the proper assessments of mouse behavior characteristics. Therefore, behavior oriented pipeline 2 is constructed of multifaceted "behavior oriented screen A" and optional sophisticated "behavior oriented screen B".
|
Behavior oriented screen A |
No. of test |
Screens | Methods | Age(weeks) | |||||||||||
| 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | |||||
| P2-01 | Behavior/ Neurology/ Psychiatry |
Light/dark transition | |||||||||||||
| P2-02 | Open-field test | ||||||||||||||
| P2-03 | Home-cage activity test | ||||||||||||||
| P2-04 | Passive avoidance test | ||||||||||||||
| P2-05 | Tail suspension test | ||||||||||||||
| P2-06 | Hot-plate test | ||||||||||||||
| P2-07 | Tail-flick test | ||||||||||||||
|
Behavior oriented screen B*2 |
No. of test |
Screens | Methods | Age(weeks) | |||||||||||
| P2-08 | Behavior/ Neurology/ Psychiatry |
Prepulse inhibition test | ND *3 | ||||||||||||
| P2-09 | Object exploration test | ||||||||||||||
| P2-10 | Fear conditioning test | ||||||||||||||
*2: "Behavior oriented screen B" will be carried out depending on the result of "Behavior oriented screen A".
*3: The age of weeks to screen is undecided.
